Cumberland Pharmaceuticals Stock Buy Hold or Sell Recommendation
| CPIX Stock | USD 1.65 0.08 5.10% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cumberland Pharmaceuticals is 'Sell'. Macroaxis provides Cumberland Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CPIX positions. The advice algorithm takes into account all of Cumberland Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Cumberland Pharmaceuticals' buy or sell advice are summarized below:
Real Value 3.32 | Target Price 8.5 | Hype Value 1.66 | Market Value 1.65 | Naive Value 1.56 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Cumberland Pharmaceuticals given historical horizon and risk tolerance towards Cumberland Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Cumberland Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Cumberland |
Execute Cumberland Pharmaceuticals Buy or Sell Advice
The Cumberland recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cumberland Pharmaceuticals. Macroaxis does not own or have any residual interests in Cumberland Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cumberland Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cumberland Pharmaceuticals Trading Alerts and Improvement Suggestions
| Cumberland Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cumberland Pharmaceuticals may become a speculative penny stock | |
| Cumberland Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 39.55 M. Net Loss for the year was (6.28 M) with profit before overhead, payroll, taxes, and interest of 32.89 M. | |
| Cumberland Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| About 44.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Cumberland Pharmaceuticals Receives New Coverage from Analysts at StockNews.com - Defense World |
Cumberland Pharmaceuticals Returns Distribution Density
The distribution of Cumberland Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Cumberland Pharmaceuticals' future price movements. The chart of the probability distribution of Cumberland Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Cumberland Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cumberland Pharmaceuticals returns is essential to provide solid investment advice for Cumberland Pharmaceuticals.
| Mean Return | -0.19 | Value At Risk | -4.91 | Potential Upside | 5.10 | Standard Deviation | 3.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cumberland Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cumberland Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cumberland Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cumberland Pharmaceuticals backward and forwards among themselves. Cumberland Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cumberland Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2023-12-31 | 18.2 K | Cresset Asset Management, Llc | 2023-12-31 | 12 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 11.3 K | Wiley Bros.-aintree Capital, Llc | 2023-12-31 | 11 K | Citadel Advisors Llc | 2023-09-30 | 5.9 K | Tower Research Capital Llc | 2023-12-31 | 5.6 K | Oakworth Capital Inc | 2023-12-31 | 3.1 K | Simplex Trading, Llc | 2023-12-31 | 237 | Royal Bank Of Canada | 2023-12-31 | 138 | Renaissance Technologies Corp | 2023-12-31 | 549.9 K | Vanguard Group Inc | 2023-12-31 | 374.3 K |
Cumberland Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 1.1M | 2.1M | 4.8M | 1.4M | (23.1K) | (22.0K) | |
| Change In Cash | 273.7K | (3.5M) | 2.3M | (7.3M) | (1.4M) | (1.4M) | |
| Free Cash Flow | 2.0M | 3.3M | 6.0M | 6.4M | 5.6M | 5.9M | |
| Depreciation | 4.4M | 4.7M | 4.6M | 5.3M | 5.8M | 6.1M | |
| Other Non Cash Items | (936.5K) | (515.7K) | (3.4M) | (2.6M) | 6.0M | 6.4M | |
| Capital Expenditures | 1.0M | 2.1M | 354.5K | 2.1M | 453.1K | 430.4K | |
| Net Income | (3.5M) | (3.4M) | (3.6M) | (5.7M) | (6.3M) | (6.0M) | |
| End Period Cash Flow | 28.2M | 24.8M | 27.0M | 19.8M | 18.3M | 27.3M | |
| Change Receivables | (1.1M) | 550.9K | (1.9M) | 4.5M | 5.2M | 5.5M | |
| Net Borrowings | 10.2M | (1.6M) | (3.5M) | 1.2M | 1.4M | 934.3K | |
| Change To Netincome | 747.1K | 3.2M | (2.9M) | (1.7M) | (2.0M) | (1.9M) | |
| Investments | 8.3M | (1.8M) | (501.9K) | (13.7M) | (1.0M) | (1.1M) |
Cumberland Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cumberland Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cumberland Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cumberland stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.22 | |
β | Beta against NYSE Composite | 0.33 | |
σ | Overall volatility | 3.70 | |
Ir | Information ratio | -0.07 |
Cumberland Pharmaceuticals Volatility Alert
Cumberland Pharmaceuticals exhibits very low volatility with skewness of 0.42 and kurtosis of 1.08. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cumberland Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cumberland Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cumberland Pharmaceuticals Fundamentals Vs Peers
Comparing Cumberland Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cumberland Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Cumberland Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cumberland Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cumberland Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cumberland Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cumberland Pharmaceuticals to competition |
| Fundamentals | Cumberland Pharmaceuticals | Peer Average |
| Return On Equity | -0.19 | -0.31 |
| Return On Asset | -0.0444 | -0.14 |
| Profit Margin | (0.16) % | (1.27) % |
| Operating Margin | (0.30) % | (5.51) % |
| Current Valuation | 21.88 M | 16.62 B |
| Shares Outstanding | 14.18 M | 571.82 M |
| Shares Owned By Insiders | 44.05 % | 10.09 % |
| Shares Owned By Institutions | 15.56 % | 39.21 % |
| Number Of Shares Shorted | 16.97 K | 4.71 M |
| Price To Earning | (16.05) X | 28.72 X |
| Price To Book | 0.78 X | 9.51 X |
| Price To Sales | 0.58 X | 11.42 X |
| Revenue | 39.55 M | 9.43 B |
| Gross Profit | 32.89 M | 27.38 B |
| EBITDA | (710.85 K) | 3.9 B |
| Net Income | (6.28 M) | 570.98 M |
| Cash And Equivalents | 18.22 M | 2.7 B |
| Cash Per Share | 1.24 X | 5.01 X |
| Total Debt | 18.43 M | 5.32 B |
| Debt To Equity | 0.50 % | 48.70 % |
| Current Ratio | 1.80 X | 2.16 X |
| Book Value Per Share | 2.10 X | 1.93 K |
| Cash Flow From Operations | 6.09 M | 971.22 M |
| Short Ratio | 1.51 X | 4.00 X |
| Earnings Per Share | (0.44) X | 3.12 X |
| Target Price | 8.5 | |
| Number Of Employees | 91 | 18.84 K |
| Beta | 0.17 | -0.15 |
| Market Capitalization | 22.12 M | 19.03 B |
| Total Asset | 81.78 M | 29.47 B |
| Retained Earnings | (17.49 M) | 9.33 B |
| Working Capital | 7.73 M | 1.48 B |
| Current Asset | 66.96 M | 9.34 B |
Note: Acquisition by John Hamm of 5500 shares of Cumberland Pharmaceuticals at 1.71 subject to Rule 16b-3 [view details]
Cumberland Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cumberland . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cumberland Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Cumberland Pharmaceuticals? Buying financial instruments such as Cumberland Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 16.1M | 21.0M | 18.4M | 11.9M | Total Assets | 84.5M | 92.9M | 81.8M | 88.1M |
Use Investing Ideas to Build Portfolios
In addition to having Cumberland Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Personal Services Thematic Idea Now
Personal Services
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Personal Services theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Personal Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cumberland Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Cumberland Stock analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Cumberland Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cumberland Pharmaceuticals. If investors know Cumberland will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cumberland Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 2.766 | Quarterly Revenue Growth 0.025 | Return On Assets (0.04) | Return On Equity (0.19) |
The market value of Cumberland Pharmaceuticals is measured differently than its book value, which is the value of Cumberland that is recorded on the company's balance sheet. Investors also form their own opinion of Cumberland Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cumberland Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cumberland Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cumberland Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cumberland Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cumberland Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cumberland Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.